Research graph
References from The Importance of C-Peptide for Developing T1D Disease-Modifying Therapies. Local targets link to admitted publications; unresolved targets remain external evidence.
Toward disease-modifying therapies in type 1 diabetes: focus on teplizumab
10.2337/dci25-0066 · 2026 · External reference
Immunotherapy-based strategies for treatment of type 1 diabetes
10.1159/000542002 · 2025 · External reference
Impact of C-peptide preservation on metabolic and clinical outcomes in the Diabetes Control and Complications Trial
10.2337/db13-0881 · 2014 · External reference
Unresolved reference
External reference
Type 1 Diabetes TrialNet: a multifaceted approach to bringing disease-modifying therapy to clinical use in type 1 diabetes
10.2337/dc17-0806 · 2018 · External reference
The Immune Tolerance Network at 10 years: tolerance research at the bedside
10.1038/nri2869 · 2010 · External reference
Immune-directed therapy for type 1 diabetes at the clinical level: the Immune Tolerance Network (ITN) experience
10.1900/rds.2012.9.359 · 2012 · External reference
INNODIA Master Protocol for the evaluation of investigational medicinal products in children, adolescents and adults with newly diagnosed type 1 diabetes
10.1186/s13063-022-06259-z · 2022 · External reference
Guidance for Industry Diabetes Mellitus—Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes
2008 · External reference
Diabetes Mellitus: efficacy Endpoints for Clinical Trials Investigating Antidiabetic Drugs and Biological Products; Draft Guidance for Industry; Availability
2023 · External reference
FDA perspective
2021 · External reference
Unresolved reference
External reference
The clinical utility of C-peptide measurement in the care of patients with diabetes
10.1111/dme.12159 · 2013 · External reference
Determination of free and total insulin and C-peptide in insulin-treated diabetics
10.2337/diab.26.1.22 · 1977 · External reference
Differential interferences of hemoglobin and hemolysis on insulin assay with the Abbott Architect-Ci8200 immunoassay
10.1016/j.clinbiochem.2014.01.026 · 2014 · External reference
2. Diagnosis and classification of diabetes: Standards of Care in Diabetes—2025
10.2337/dc25-s002 · 2025 · External reference
Orphan Drug Regulations
2013 · External reference
Prevalence of type 1 diabetes among US children and adults by age, sex, race, and ethnicity
10.1001/jama.2024.2103 · 2024 · External reference
Socioeconomic inequalities in mortality, morbidity and diabetes management for adults with type 1 diabetes: a systematic review
10.1371/journal.pone.0177210 · 2017 · External reference
Low-dose anti-thymocyte globulin preserves C-peptide, reduces HbA1c, and increases regulatory to conventional T-cell ratios in new-onset type 1 diabetes: two-year clinical trial data
10.2337/db19-0057 · 2019 · External reference
Teplizumab and β-cell function in newly diagnosed type 1 diabetes
10.1056/nejmoa2308743 · 2023 · External reference
Changes in key recruitment performance metrics from 2008–2019 in industry-sponsored phase III clinical trials registered at ClinicalTrials.gov
10.1371/journal.pone.0271819 · 2022 · External reference
C-peptide and metabolic outcomes in trials of disease modifying therapy in new-onset type 1 diabetes: an individual participant meta-analysis
10.1016/s2213-8587(23)00267-x · 2023 · External reference
Unresolved reference
External reference
Teplizumab for treatment of type 1 diabetes (Protégé study): 1-year results from a randomised, placebo-controlled trial
10.1016/s0140-6736(11)60931-8 · 2011 · External reference
C-peptide levels in subjects followed longitudinally before and after type 1 diabetes diagnosis in TrialNet
10.2337/dc19-2288 · 2020 · External reference
Evidence for C-peptide as a validated surrogate to predict clinical benefits in trials of disease-modifying therapies for type 1 diabetes
10.2337/dbi23-0012 · 2024 · External reference
C-peptide is the appropriate outcome measure for type 1 diabetes clinical trials to preserve β-cell function: report of an ADA workshop, 21–22 October 2001
10.2337/diabetes.53.1.250 · 2004 · External reference
Hypoglycemic agents and glycemic variability in individuals with type 2 diabetes: a systematic review and network meta-analysis
10.1177/14791641221106866 · 2022 · External reference
Islet transplantation versus standard of care for type 1 diabetes complicated by severe hypoglycemia from the Collaborative Islet Transplant Registry and the T1D Exchange Registry
2025 · External reference
Effect of intensive therapy on residual beta-cell function in patients with type 1 diabetes in the diabetes control and complications trial. A randomized, controlled trial
10.7326/0003-4819-128-7-199804010-00001 · 1998 · External reference
β-Cell function and the development of diabetes-related complications in the Diabetes Control and Complications Trial
10.2337/diacare.26.3.832 · 2003 · External reference
Closed-loop therapy and preservation of C-peptide secretion in type 1 diabetes
10.1056/nejmoa2203496 · 2022 · External reference
Effect of tight glycemic control on pancreatic beta cell function in newly diagnosed pediatric type 1 diabetes: a randomized clinical trial
10.1001/jama.2023.2063 · 2023 · External reference
Residual β cell function in long-term type 1 diabetes associates with reduced incidence of hypoglycemia
10.1172/jci143011 · 2021 · External reference
Use of surrogate outcomes in US FDA drug approvals, 2003–2012: a survey
10.1136/bmjopen-2015-007960 · 2015 · External reference
Unresolved reference
External reference
Association of diabetic ketoacidosis at onset, diabetes technology uptake, and clinical outcomes after 1 and 2 years of follow-up: a collaborative analysis of pediatric registries Involving 9,269 children with type 1 diabetes from nine countries
10.2337/dc24-2483 · 2025 · External reference
Call for standardization of C-peptide measurement
10.1177/19322968251362848 · 2025 · External reference
Unresolved reference
External reference
Unresolved reference
External reference
Prevention and reversal of type 1 diabetes—past challenges and future opportunities
10.2337/dc15-0349 · 2015 · External reference
Combination immunotherapy for type 1 diabetes
10.1007/s11892-017-0878-z · 2017 · External reference
